Edition:
India

Atossa Genetics Inc (ATOS.OQ)

ATOS.OQ on NASDAQ Stock Exchange Capital Market

0.31USD
2:29am IST
Change (% chg)

$-0.02 (-5.97%)
Prev Close
$0.33
Open
$0.33
Day's High
$0.33
Day's Low
$0.31
Volume
86,177
Avg. Vol
602,297
52-wk High
$1.85
52-wk Low
$0.28

Latest Key Developments (Source: Significant Developments)

Atossa Genetics posts Q3 loss per share ‍$0.18​
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Atossa Genetics Inc :Atossa Genetics announces third quarter 2017 financial results and provides company update.Atossa Genetics Inc qtrly loss per share ‍$0.18​.  Full Article

L1 Capital Global Opportunities Master Fund reports 9.01 pct passive stake in ‍atossa Genetics, as of Oct. 26
Saturday, 4 Nov 2017 

Nov 3 (Reuters) - L1 Capital Global Opportunities Master Fund Ltd: :L1 capital global opportunities master fund ltd reports 9.01% passive stake in ‍atossa genetics inc, as of october 26, 2017 - SEC filing‍​.  Full Article

Empery Asset Management reports 9.01 pct passive stake in Atossa Genetics
Wednesday, 1 Nov 2017 

Oct 31 (Reuters) - Empery Asset Management LP::Empery Asset Management LP reports 9.01 percent passive stake in Atossa Genetics as of Oct 26 - SEC filing‍​.  Full Article

Atossa Genetics announces pricing of $5.1 million public offering
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Atossa Genetics Inc :Atossa Genetics announces pricing of $5.1 million public offering of common stock.Says public offering of 11.5 million common shares priced at $0.44per share.  Full Article

Atossa Genetics announces proposed public offering of common stock
Thursday, 26 Oct 2017 

Oct 25 (Reuters) - Atossa Genetics Inc ::Atossa Genetics announces proposed public offering of common stock.Says ‍intends to offer and sell shares of its common stock in an underwritten public offering​.  Full Article

Atossa Genetics announces preliminary results from Phase 1 study of topical Endoxifen
Thursday, 14 Sep 2017 

Sept 14 (Reuters) - Atossa Genetics Inc ::Atossa Genetics announces preliminary results from Phase 1 study of topical Endoxifen.Atossa Genetics Inc says expects to announce results from oral arm of Phase 1 study in next 30-60 days.Atossa Genetics Inc says ‍all objectives were successfully met in trial​.Atossa Genetics says‍ no clinically significant safety signals,no clinically significant adverse events in participants receiving topical Endoxifen​.  Full Article

Atossa Genetics qtrly loss per share $0.45
Friday, 12 May 2017 

May 11 (Reuters) - Atossa Genetics Inc ::Atossa Genetics announces first quarter 2017 financial results and provides company update.Qtrly loss per share $0.45.  Full Article

Atossa prices underwritten public offering of 1,150,000 common shares
Wednesday, 31 Aug 2016 

Atossa Genetics Inc : Atossa genetics, inc. Prices underwritten public offering of 1,150,000 common shares .Says public offering of 1.15 million common shares priced at $2.50per share.  Full Article

Atossa Genetics announces proposed public offering of common stock
Wednesday, 31 Aug 2016 

Atossa Genetics Inc : Announces proposed public offering of common stock .Intends to use proceeds for working capital and to fund other general corporate purposes, including funding costs of clinical trials.  Full Article

Atossa Genetics says announced a reverse split of its common stock at a ratio of 1-for-15
Thursday, 25 Aug 2016 

Atossa Genetics Inc : Atossa Genetics announces reverse stock split . Says announced a reverse split of its common stock at a ratio of 1-for-15, effective August 26, 2016 .Number of outstanding common shares will be reduced from approximately 39.57 million shares to approximately 2.67 million shares.  Full Article

BRIEF-Atossa Genetics posts Q3 loss per share ‍$0.18​

* Atossa Genetics announces third quarter 2017 financial results and provides company update